Opinion Article: This is an article written by Ivan N. Rich of HemoGenix, Inc., Colorado Springs, CO, USA. It is an opinion piece that reflects views and positions of the author. It does not reflect the views of BioInformant Worldwide, LLC.

As a stem cell and cord blood industry blog, it is our role to spread discussion and allow a voice to varying opinions, perspectives, and areas of scientific expertise. If you have a reaction to this article, ask yourself, why am I reacting? How do I perceive current techniques for cord blood testing and assessment? If you have thoughts, they are encouraged in the comments section below.

November 24, 2015; HemoGenix, Inc. – The passage by voice vote of H.R. 2820, otherwise known as The Stem Cell Therapeutic and Research Reauthorization Act of 2015 through the U.S. House of Representatives [1] has been lauded by many in the cord blood community, including the Cord Blood Association (CBA) that promoted the bill. There is a good chance the Bill will become law, because health issues usually have bipartisan support. Although patients requiring a cord blood stem cell transplant have been helped by previous Bills, they have nevertheless not benefited from the principle purpose of this Bill, namely to provide high-quality cord blood stem cells for transplantation. [Read more…]